IPO - Profile

RxSight, Inc.

Health Care > Ophthalmic Goods



We are a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight Light Adjustable Lens system (“RxSight system”), comprised of our RxSight Light Adjustable Lens (“LAL”), RxSight Light Delivery Device (“LDD”) and accessories, is the first and only commercially available intraocular lens (“IOL”) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Our LAL is made of proprietary photosensitive material that changes shape in response to specific patterns of ultraviolet (“UV”) light generated by our LDD.

With More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 7,400,000 Positive High 34.77%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jul, 2021

Offer 30 Jul, 2021

Look Ahead

Lock Up Expiry Jan 30, 2022

IPO Terms

Offer Price $16.00
Offer Size 7M

Market Sentiments

Stock Price